Might dolutegravir be part of a functional cure for HIV?
Can J Microbiol
; 62(5): 375-82, 2016 May.
Article
en En
| MEDLINE
| ID: mdl-27031127
ABSTRACT
Antiretroviral therapy (ART) has greatly decreased HIV-related morbidity and mortality. However, HIV can establish viral reservoirs that evade both the immune system and ART. Dolutegravir (DTG) is a second-generation integrase strand transfer inhibitor (INSTI) related to the first-generation INSTIs raltegravir (RAL) and elvitegravir (EVG). DTG shows a higher genetic barrier to the development of HIV-1 resistance than RAL and EVG. More interestingly, clinical resistance mutations to DTG in treatment-naïve patients have not been observed to date. This review summarizes recent studies on strategies toward a cure for HIV, explores resistance profiles of DTG, and discusses how DTG might help in finding a functional cure for HIV.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Infecciones por VIH
/
Inhibidores de Integrasa VIH
/
Compuestos Heterocíclicos con 3 Anillos
Límite:
Humans
Idioma:
En
Revista:
Can J Microbiol
Año:
2016
Tipo del documento:
Article
País de afiliación:
Canadá